Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II

To overcome poor pharmacokinetics and toxicity of triptolide (TPL), a natural compound that exhibits potent anticancer activities, we developed a novel antibody-drug conjugate (ADC) to specifically deliver TPL to epidermal growth factor receptor (EGFR)-overexpressing non-small cell lung cancer (NSCL...

Full description

Bibliographic Details
Main Authors: Keqiang Zhang, Yuelong Ma, Yuming Guo, Ting Sun, Jun Wu, Rajendra P. Pangeni, Min Lin, Wendong Li, David Horne, Dan J. Raz
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
antibody-drug conjugate
targeted therapy
triptolide
cetuximab
EGFR
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520301054

Internet

http://www.sciencedirect.com/science/article/pii/S2372770520301054

Similar Items